Harbour Investments’s BridgeBio Pharma BBIO Stock Holding History

Harbour Investments’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$968	Buy	13 +12	+1,200%	+$840	﹤0.01%	4227
2026 Q1	$74	Buy	+1	New	+$72	﹤0.01%	4541
2021 Q4	–	Sell	-2	Closed	–	–	2705
2021 Q3	$0	Buy	2 +1	+100%	+$54	﹤0.01%	3729
2021 Q2	$0	Hold	1	–	–	﹤0.01%	3764
2021 Q1	$0	Buy	+1	New	+$65	﹤0.01%	3594

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Harbour Investments's BBIO Position: Q2 2026 in Review

Harbour Investments increased its BridgeBio Pharma (BBIO) stake by 1,200% in Q2 2026, buying an estimated $840 and bringing the position to 13 shares worth $968. The position accounts for ﹤0.01% of the portfolio, ranked #4227.

Harbour Investments first reported a position in BBIO in Q1 2021 and has held it in 5 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Harbour Investments held 13 shares of BridgeBio Pharma worth $968 as of Q2 2026.
Harbour Investments bought 12 BridgeBio Pharma shares in Q2 2026, an estimated $840.
BridgeBio Pharma made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4227 holding.
Harbour Investments first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 5 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.